PHAXIAM Therapeutics SA (PHXM)

US29604W2070 - ADR

3.1  -0.02 (-0.64%)

After market: 3.1 0 (0%)

Full estimates are only available for subscribed users, you can see which data is available below.

Examples of complete estimate data are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional estimates and surprises .

Yearly Revenue, EBIT, EBITDA and EPS Analyst Estimates
2020 2021 2022 2023 2024 2025 2026
Revenue
YoY % growth
3.718M
-42.45%		4.18M
12.43%		6.648M
59.04%
-100.00%
EBITDA
YoY % growth
-63.841M
-14.79%		-51.138M
19.90%		-22.528M
55.95%		-25.806M
-14.55%
EBIT
YoY % growth
-68.832M
-14.14%		-56.515M
17.89%		-27.147M
51.96%		-26.418M
2.69%
Operating Margin
-1,851.32%-1,352.03%-408.35%N/A
EPS
YoY % growth
N/A
-5.11%		N/A
17.43%		N/A
51.41%		-1.62
77.73%

All data in EUR

Quarterly Revenue, EBIT, EBITDA and EPS Analyst Estimates
Q4 / 23
EPS
Q2Q % growth		-0.14
86.11%
Revenue
Q2Q % growth		N/A
EBITDA
Q2Q % growth		N/A
EBIT
Q2Q % growth		N/A

All data in EUR

Recent Earnings VS Estimates Surprises (EUR)
PeriodReportedEstimateDifferenceSurprise
Q3 2023
Q2Q % growth
93.89%		-0.12%
Q2 2023
Q2Q % growth
80.53%		-0.12%
Q1 2023
Q2Q % growth
57.45%		-1.10%
Q4 2022
Q2Q % growth
62.50%		-0.99%
Q3 2022
Q2Q % growth
Q2 2022
Q2Q % growth
Q1 2022
Q2Q % growth
Q4 2021
Q2Q % growth
Q3 2021
Q2Q % growth
Q2 2021
Q2Q % growth
Recent Revenue VS Estimates Surprises (EUR)
PeriodReportedEstimateDifferenceSurprise
Q3 2023
Q2Q % growth		 197K
-58.00%		%
Q2 2023
Q2Q % growth		 278K
-70.86%		%
Q1 2023
Q2Q % growth
-88.24%		299.88K%
Q4 2022
Q2Q % growth		 5.694M
272.16%		714K4.98M697.48%
Q3 2022
Q2Q % growth
Q2 2022
Q2Q % growth
Q1 2022
Q2Q % growth
Q4 2021
Q2Q % growth
Q3 2021
Q2Q % growth
Q2 2021
Q2Q % growth
EPS and Revenue Revisions
Next Q (1 month) Next Q (3 month) Next Year (1 month) Next Year (3 month)
EPS0% 0% -15.5% -0.34%
RevenueN/A N/A N/A N/A